Investigational drug · Phase 2
ETX-19477
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ETX-19477"
First trial start
2024
May 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ETX-19477", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced or Metastatic Solid Tumors
- Breast Cancer
- Ovarian Cancer
- Prostate Cancer
- Epithelial Ovarian Cancer
- BRCA2 Mutation
- ER+ Breast Cancer
- Castrate Resistant Prostate Cancer
- BRCA1 Mutation
- BRCA Mutation
Approved drugs for the same conditions: Breast cancer · Prostate cancer · Ovarian cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "ETX-19477" as an intervention, largest first.
858 Therapeutics, Inc.Industry
NCT06395519 · 120 participants (planned) · Start May 13, 2024 · Primary completion Dec 2026
Drug: ETX-19477 · For: Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer and 10 more
Sites: Phoenix, Arizona; New Haven, Connecticut; Jacksonville, Florida · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced or Metastatic Solid Tumors
- ERAS-007Phase 22 trials
Erasca, Inc. · Advanced or Metastatic Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
- ERAS-601Phase 21 trial
Erasca, Inc. · Advanced or Metastatic Solid Tumors
- TAK-188Phase 21 trial
Takeda · Advanced or Metastatic Solid Tumors
- WTX-330Phase 21 trial
Werewolf Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.